MAPK3 and small cell lung carcinoma: Similar up-regulation of p-ERK1/2 was observed as early as 24 h post-treatment with GSK525762 in NCI-H526 SCLC cells that lack mutations in the RAS pathway (Fig. 4c, d), indicating that this mechanism is likely relevant in both the RAS pathway mutant and WT setting.